期刊文献+

促红素联合铁剂治疗肾性贫血的疗效分析 被引量:4

Analysis of Efficacy of Erythropoietin Combined with Iron on Renal Anemia
下载PDF
导出
摘要 目的探讨促红细胞生成素联合蔗糖铁治疗肾性贫血的临床疗效。方法选取2016年1月至2107年1月我院收治的肾性贫血74例,按随机数字表法分为两组,对照组37例,采取促红细胞生成素(EPO)治疗,观察组37例,在对照组治疗基础上联合蔗糖铁注射液治疗,治疗4w为1个疗程,均治疗1个疗程后,测定两组治疗前后血红蛋白(Hb)、血细胞比容(HCT)、血清铁蛋白(SF)、转铁蛋白(TRF)水平变化,比较两组治疗效果,并比较两组用药安全性。结果观察组治疗后Hb、HCT、SF水平均高于对照组,TRF水平低于对照组(P<0.05);观察组总有效率高于对照组(P<0.05);且两组无明显不良反应发生。结论对肾性贫血患者采取促红素联合铁剂治疗的效果较好,且用药安全。 Objective To investigate the clinical efficacy of erythropoietin combined with iron on renal anemia. Methods 74 cases of kidney from January 2016 to January 2107 in our hospital were anemia, were randomly divided into two groups, 37 cases in the control group, take erythropoietin(EPO) treatment, 37 cases in the observation group in the control group based on the combined treatment of Iron Sucrose Injection, 4 W treatment for 1 courses of treatment, were treated for 1 after treatment, the determination of the two groups before and after treatment of hemoglobin(Hb), hematocrit(HCT), serum ferritin(SF), transferrin(TRF) levels, the treatment effects were compared between the two groups, and compare two groups of drug safety. Results After treatment, the levels of Hb, HCT and SF in the observation group were higher than those in the control group, and the level of TRF was lower than that of the control group(P<0.05). The total effective rate of the observation group was higher than that of the control group(P<0.05). Conclusion The use of erythropoietin combined with iron therapy has good treatment effect on patients with renal anemia, and drug safety.
作者 季延中
出处 《智慧健康》 2017年第19期97-98,共2页 Smart Healthcare
关键词 肾性贫血 血液透析 促红细胞生成素 蔗糖铁注射液 Renal anemia Blood dialysis Hemopoietin Venofer
  • 相关文献

参考文献5

二级参考文献39

  • 1钱玉润,周令芳,胡春,沈国勇,陈佩华.左旋卡尼汀对血液透析患者心功能改善的作用[J].临床肾脏病杂志,2005,5(2):53-55. 被引量:8
  • 2雷建蓉.肾性贫血治疗的现状及展望[J].国外医学(移植与血液净化分册),2005,3(3):7-10. 被引量:35
  • 3黄雯,刘平.透析手册[M].北京:中信出版社,2004:176—177. 被引量:10
  • 4MAGGIONI A P,OPASICH C,ANAND I,et al.Anemia in patients with heart failure:prevalence and prognostic role in a controlled trial and in clinical practice[J].J Card Fail,2005,11(2):91-98. 被引量:1
  • 5O′MEARA E,MURPHY C,MCMURRAY J J.Anemia and heart failure[J].Curr Heart Fail Rep,2004,1(4):176-182. 被引量:1
  • 6ANAND I,MCMURRAY J J,WHITMORE J,et al.Anemia and its relationship to clinical outcome in heart failure[J].Circulation,2004,110(2):149-154. 被引量:1
  • 7O′MEARA E,CLAYTON T,MCENTEGART M B,et al.Clinical correlates and consequences of anemia in a broad spectrum of patients with heart failure:results of the Candesartan in Heart Fai lure:Assessment of Reduction in Mortality and Morbidity (CHARM) Program[J].Circulation,2006,113(7):986-994. 被引量:1
  • 8WESTENBRINK B D,VISSER F W,VOORS A A,et al.Anaemia in chronic heart failure is not only related to impaired renal perfusion and blunted erythropoietin production,but to fluid retention as well[J].Eur Heart J,2007,28(2):166-171. 被引量:1
  • 9ANAND I S.Heart failure and anemia:mechanisms and pathophysiology[J].Heart Fail Rev,2008,13(4):379-386. 被引量:1
  • 10FELKER G M,GATTIS W A,LEIMBERGER J D,et al.Usefulness of anemia as a predictor of death and rehospitalization in patients with decompensated heart failure[J].Am J Cardiol,2003,92(5):625-628. 被引量:1

共引文献41

同被引文献28

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部